Abstract 21P
Background
Clinical trial registries record the proposed and actual completion date of studies. Study duration affects budget, personnel, governance and ethics. To our knowledge, no data exists comparing estimated time to study completion with actual completion date. Using breast cancer trials as an exemplar, we analyzed differences between estimated and actual duration of clinical trials.
Methods
A sophisticated artificial intelligence (AI) tool, Risklick AI®1-3 analysed clinical trial registry fields for proposed trial completion (entered at time of study registration) compared to date entered for study completion. This technology collects and unifies trial data from all 18 public registries, including clinicaltrials.gov and WHO. The comprehensive search performed on 15.3.23 for period 2000 – 2023 used 101 keywords to cover breast cancer subtypes in completed trials. Trials were analyzed according to factors postulated to impact duration: disease extent, histological subtype, phase, number of eligibility criteria, sample size, country and sponsor. Delay was defined as the additional time required to complete the trial compared to the estimated study completion date, with a tolerance of 30 days.
Results
582 trials, involving 104’384 patients, recorded both planned and actual completion dates. Overall, 21.6% were finished early, 7.9% on time, and 70.4% had delay, of mean 31.7 +/- 25.6 months [standard deviation], ranging 1 - 155 months. The mean delay was similar for trials analysed by disease extent, breast cancer subtype, phase, number of eligibility criteria, sample size, country, or sponsor type.
Conclusions
This large real-world dataset revealed an average delay in completion of 2.5-year for 70% of breast cancer trials, independent of multiple factors commonly thought to affect trial duration. This data should be considered when planning, budgeting and setting participant and community expectations for trials. Tools to accurately predict trial duration and efforts to reduce delays are needed.
References: 1. www.risklick.ch 2. Front Digit Health. 2021;3 3. Pharmacology. 2021;106(5-6):244-253.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Bern.
Funding
Has not received any funding.
Disclosure
P. Khlebnikov, F. Meer, Q. Haas: Financial Interests, Personal, Full or part-time Employment: Risklick AG. P. Amini: Financial Interests, Personal, Ownership Interest: Risklick AG. E. Segelov: Financial Interests, Personal, Invited Speaker, Limbic are a medical educational company running various seminars which I have participated in as an invited speaker/Chair: Limbic; Financial Interests, Personal, Invited Speaker, webinar on colorectal cancer 28/02/21: Servier; Financial Interests, Institutional, Local PI, As head of the Oncology Cancer clinical trials at Monash Health (until 15 Aug 2022) where there were >200 trials active, there were the usual commercial arrangements to run the trials with the institution. There was no personal financial benefit from any: > 15 different companies. All other authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract